Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061312 | 1.00 | PREP (0.44) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL6159871 | 1.00 | PREP (0.44) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL29484188 | 0.95 | CTSK (0.46) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL2580872 | 0.93 | PREP (0.39) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL721602 | 0.90 | PREP (0.38) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL31587441 | 0.89 | CTSK (0.45) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL11803999 | 0.87 | CTSK (0.38) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL4969025 | 0.87 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA2 | |
| SCHEMBL5696168 | 0.87 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA2 | |
| SCHEMBL23771884 | 0.86 | CTSK (0.38) | PREPCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| WO-2026090173-A1 | MODIFIED SELF-IMMOLATING MOIETIES IN ANTIBODY-DRUG CONJUGATES | CODEABLE THERAPEUTICS, INCORPORATED (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026085848-A1 | NANO-DRUG DELIVERY SYSTEM MODIFIED WITH PHENOLIC ACID OR DIPEPTIDE FOR INCREASING ORAL ABSORBABILITY AND BIOAVAILABILITY, AND USE THEREOF | 四川大学 | 2026-04-30 | — | — | WO | disclosed |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | ZEVRA THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-10-16 | — | — | US | disclosed |
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| EP-0654041-B1 | PEPTIDYL 4-AMINO-2,2-DIFLUORO-3-OXO-1,6-HEXANEDIOIC ACID DERIVATIVES AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0838471-A1 | PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-5739279-A | Peptidyl 4-amino-2,2-difluoro-3-oxo-1,6-hexanedioic acid derivatives as antiinflammatory agents | PFIZER INC. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0761678-A1 | Fluorine-containing anthracycline derivatives having hydroxyl group(s) mono- or di-o-aminoalkanoylated in the sugar moiety thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0632808-A1 | ANTIVIRAL PEPTIDES | Pfizer Limited (GB) | 1995-01-11 | — | — | EP | disclosed |
| WO-1993023373-A1 | N-[N'-(5-AMINO-4-HYDROXY-ACYLOYL)-α-AMINOACYLOYL] SUBSTITUTED HETEROCYCLES AND THEIR USE AS ANTIVIRAL AGENTS | PFIZER LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
| EP-0569598-A1 | BENZOXAZINONE DERIVATIVE | JAPAN TOBACCO INC. (JP) | 1993-11-18 | — | — | EP | disclosed |
| WO-1993019059-A1 | ANTIVIRAL PEPTIDES | PFIZER LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
| EP-0337714-A2 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4237047-A | FLUORESCENT SUBSTRATE FOR MEASURING ENZYME ACTIVITY | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ARG1, ARG2, PRMT1 | PREP 867/4885CTSK 1677/4885CTSS 1500/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | PREP 2966/4885CTSK 595/4885CTSS 977/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | PREP 86/4885CTSK 1074/4885CTSS 628/4885 |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | OPRM1, OPRD1, OPRK1 | PREP 2459/4885CTSK 4223/4885CTSS 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.